Company Overview

Lisata Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company focused on the development of targeted therapies intended to improve the delivery and effectiveness of anti-cancer treatments. The company operates within the oncology and biopharmaceutical industries, with a primary emphasis on investigational therapeutics designed to enhance penetration of chemotherapeutics and immunotherapies into solid tumors. Its lead product candidate is CEND-1, a peptide-based investigational agent being studied in combination with standard-of-care cancer treatments across multiple solid tumor indications.

The company’s primary business activity is research and development rather than commercial product sales, and its revenue profile has historically been tied to financing activities, licensing arrangements, and collaborations rather than recurring operating revenue. Lisata evolved through a series of corporate restructurings and strategic shifts, including prior operations under different corporate identities before focusing on oncology therapeutics and adopting the Lisata Therapeutics name. The company positions itself around tumor microenvironment modulation and enhanced drug delivery, seeking differentiation through combination-based oncology strategies.

Business Operations

Lisata Therapeutics conducts operations primarily through its oncology development platform centered on CEND-1 and related therapeutic technologies. The company’s activities include clinical trial management, regulatory development, intellectual property management, and strategic collaboration with research institutions and pharmaceutical companies. Its operating model is typical of clinical-stage biotechnology firms, relying on outsourced manufacturing, contract research organizations, and external clinical trial partners while maintaining internal oversight of development strategy and regulatory planning.

The company’s operations are primarily based in the United States, though its clinical programs have involved international trial sites and partnerships. Lisata has pursued collaborative arrangements with academic institutions and healthcare organizations to evaluate CEND-1 in pancreatic cancer and other solid tumors. The company controls intellectual property associated with tumor-penetrating peptide technology and focuses on combination regimens involving chemotherapy, immunotherapy, and other anti-cancer agents. Public filings indicate that the company’s operational expenditures are concentrated in research and development activities and general corporate administration.

Strategic Position & Investments

Lisata’s strategic direction centers on advancing clinical-stage oncology assets through combination therapy studies and potential partnering opportunities with larger pharmaceutical organizations. The company has prioritized development of CEND-1 across difficult-to-treat cancers, particularly pancreatic ductal adenocarcinoma and other solid tumors where drug delivery limitations may reduce treatment effectiveness. Its strategy includes generating clinical data that could support licensing agreements, co-development arrangements, or future commercialization pathways.

The company has invested heavily in clinical development programs, regulatory submissions, and intellectual property protection associated with tumor-targeting peptide technologies. Lisata’s public disclosures indicate continued evaluation of additional oncology indications and combination approaches involving chemotherapy and immuno-oncology agents. The company does not currently operate a diversified portfolio of commercial subsidiaries, but it has maintained relationships with external clinical and research partners to expand the applicability of its platform technology. Data regarding large-scale acquisitions or broad portfolio holdings is inconclusive based on available public sources.

Geographic Footprint

Lisata Therapeutics is headquartered in the United States, with corporate operations centered in New Jersey. Its primary market focus remains North America, particularly the U.S. biotechnology and clinical research ecosystem. The company’s development activities are tied to U.S. regulatory oversight, including interactions with the Food and Drug Administration, while several clinical initiatives have involved international trial participation.

The company’s operational footprint extends into selected international regions through multicenter clinical studies, research collaborations, and outsourced development relationships. While Lisata does not maintain the extensive global commercial infrastructure associated with large pharmaceutical manufacturers, its clinical programs and partnership activities have included participation from institutions in Europe and other international healthcare markets. Its influence internationally is currently tied more to clinical development and licensing potential than to direct commercial operations.

Leadership & Governance

Lisata Therapeutics is led by an executive team with backgrounds in biotechnology, oncology drug development, finance, and public-company governance. Leadership strategy has emphasized advancing clinical oncology assets through disciplined capital allocation, external partnerships, and targeted clinical development programs. The company operates under a publicly traded corporate governance structure and files regular disclosures through the SEC as a Nasdaq-listed issuer.

Key executives and directors associated with the company include:

• David J. Mazzo, Ph.D. – Chief Executive Officer and Chairman
• Kristin R. Taylor – Chief Financial Officer
• Dennis Podlesak – Director
• Michael S. Weiss – Director
• James Sapirstein – Director

Public disclosures indicate that management’s strategic focus has centered on progressing late-stage oncology development opportunities, strengthening clinical evidence for CEND-1, and positioning the company for potential strategic collaborations within the oncology sector.